Adenosine Monophosphate

• 

  Subject Areas on Research

  • A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. 
  • A fatal case of coronavirus disease 2019 in a patient with common variable immunodeficiency. 
  • A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. 
  • Adenine nucleotides of ischemic intestine do not reflect injury. 
  • Adenosine nucleotides in bile. 
  • Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism. 
  • Adenylosuccinate Is an Insulin Secretagogue Derived from Glucose-Induced Purine Metabolism. 
  • Advances in antiplatelet therapy: agents in clinical development. 
  • Alkaline Phosphatase, Soluble Extracellular Adenine Nucleotides, and Adenosine Production after Infant Cardiopulmonary Bypass. 
  • An engineered liver glycogen phosphorylase with AMP allosteric activation. 
  • Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? 
  • Aspirin and clopidogrel resistance: consideration and management. 
  • Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. 
  • Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week. 
  • Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. 
  • Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry. 
  • Cangrelor and Heparin for Pulmonary Thromboendarterectomy in Heparin-Induced Thrombocytopenia. 
  • Cangrelor for the treatment of patients with Arterial Thrombosis. 
  • Cangrelor use prior to left ventricular assist device surgery: a case series. 
  • Cangrelor: an emerging therapeutic option for patients with coronary artery disease. 
  • Catecholamine stimulated myocardial adenylate cyclase: effects of nucleotides. 
  • Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. 
  • Characterization of nucleotide binding sites on chloroplast coupling factor 1. 
  • Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019. 
  • Crystal structures of adenine phosphoribosyltransferase from Leishmania donovani. 
  • Deoxyribonucleic acid ligase. A steady state kinetic analysis of the reaction catalyzed by the enzyme from Escherichia coli. 
  • Deoxyribonucleic acid ligase. Isolation and physical characterization of the homogeneous enzyme from Escherichia coli. 
  • Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. 
  • Effects of hypoxia and toxicant exposure on adenylate energy charge and cytosolic ADP concentrations in abalone. 
  • Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. 
  • Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study. 
  • Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process. 
  • Endogenous production of extracellular adenosine by trabecular meshwork cells: potential role in outflow regulation. 
  • Enzymatic joining of polynucleotides. XI. Reversal of Escherichia coli deoxyribonucleic acid ligase reaction. 
  • Formation of a free acyl adenylate during the activation of 2-propylpentanoic acid. Valproyl-AMP: a novel cellular metabolite of valproic acid. 
  • Hydrolysis of template and newly synthesized deoxyribonucleic acid by the 3' to 5' exonuclease activity of the T4 deoxyribonucleic acid polymerase. 
  • Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. 
  • Improving SARS-CoV-2 structures: Peer review by early coordinate release. 
  • Influence of allosteric ligands on the activity and aggregation of rabbit muscle phosphofructokinase. 
  • Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. 
  • Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report. 
  • Investigating the Role of Class I Adenylate-Forming Enzymes in Natural Product Biosynthesis. 
  • Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. 
  • Modeling the biochemical differences between rabbit muscle and human liver phosphorylase. 
  • Molecular basis of the biological function of molybdenum. Developmental patterns of sulfite oxidase and xanthine oxidase in the rat. 
  • NMR-based Structural Analysis of Threonylcarbamoyl-AMP Synthase and Its Substrate Interactions. 
  • Nicotinamide adenine dinucleotide (NAD) and its metabolites inhibit T lymphocyte proliferation: role of cell surface NAD glycohydrolase and pyrophosphatase activities. 
  • Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. 
  • Pharmacogenetic variants and risk of remdesivir-associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID-19. 
  • Platelet inhibition to target reperfusion injury trial: Rationale and study design. 
  • Platelet inhibition with cangrelor in patients undergoing PCI. 
  • Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. 
  • Purification of the AMP-activated protein kinase on ATP-gamma-sepharose and analysis of its subunit structure. 
  • Purine synthesis promotes maintenance of brain tumor initiating cells in glioma. 
  • Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data. 
  • Remdesivir for the Treatment of Covid-19 - Final Report. 
  • Remdesivir: Preliminary Data and Clinical Use Versus Recommended Use. 
  • Remdesivir: a pendulum in a pandemic. 
  • Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial. 
  • Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery. 
  • Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. 
  • The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells. 
  • Using "old" medications to fight new COVID-19: Re-purposing with a purpose. 
  • What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention? 
  • YbiV from Escherichia coli K12 is a HAD phosphatase.